Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-005938
Filing Date
2021-05-05
Accepted
2021-05-05 16:30:57
Documents
58
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ettx-20210331x10q.htm   iXBRL 10-Q 965869
2 EX-31.1 ettx-20210331xex31d1.htm EX-31.1 13568
3 EX-31.2 ettx-20210331xex31d2.htm EX-31.2 12841
4 EX-32.1 ettx-20210331xex32d1.htm EX-32.1 8761
  Complete submission text file 0001558370-21-005938.txt   4630127

Data Files

Seq Description Document Type Size
5 EX-101.SCH ettx-20210331.xsd EX-101.SCH 45683
6 EX-101.CAL ettx-20210331_cal.xml EX-101.CAL 36750
7 EX-101.DEF ettx-20210331_def.xml EX-101.DEF 160996
8 EX-101.LAB ettx-20210331_lab.xml EX-101.LAB 381682
9 EX-101.PRE ettx-20210331_pre.xml EX-101.PRE 292012
10 EXTRACTED XBRL INSTANCE DOCUMENT ettx-20210331x10q_htm.xml XML 696577
Mailing Address 35 GATEHOUSE DRIVE WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE WALTHAM MA 02451 (781) 810-0120
Entasis Therapeutics Holdings Inc. (Filer) CIK: 0001724344 (see all company filings)

EIN.: 824592913 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38670 | Film No.: 21893871
SIC: 2834 Pharmaceutical Preparations